All In Biotech

Drug Trial Radar · NCT01141452

Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD

Retrospective, Real-life Evaluation of the Effectiveness, Cost-effectiveness and Direct Healthcare Costs of Qvar Pressurised Metered-dose Inhaler (pMDI) Compared With Beclometasone Dipropionate pMDI and Fluticasone pMDI in the Management of Chronic Obstructive Pulmonary Disease (COPD) in a Representative UK Primary Care Patient Population

Last checked: Nov 19, 2026Latest source record: Mar 8, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

815,377

Actual

Start

Jan 2001

Primary completion

Jun 2007

Study completion Jul 2007

Sponsor

Lead sponsor
Research in Real-Life LtdResearch network
Sponsor type
Research network
Collaborators
Teva Branded Pharmaceutical Products R&D, Inc.
First posted
Jun 10, 2010

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to compare the effectiveness, cost-effectiveness and direct healthcare costs of managing chronic obstructive pulmonary disease (COPD) in primary care patients with evidence of COPD who either initiate inhaled corticosteroid (ICS) therapy, or have an increase in their ICS dose, as hydrofluoroalkane (HFA) beclometasone dipropionate (BDP) (hereafter Qvar®), CFC-BDP (hereafter BDP) and fluticasone propionate (FP) via pressurised metered-dose inhalers.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Extra-fine hydrofluoroalkane beclomethasone MDIDrug

    Step-up in baseline BDP-equivalent ICS dose

  • Chlorofluorocarbon beclomethasone metered dose inhalerDrug

    Step-up in baseline BDP-equivalent ICS dose

  • Fluticasone propionate metred dose inhalerDrug

    Step-up in baseline BDP-equivalent ICS dose

  • Fluticasone propionate metred dose inhalerDrug

    Initiation of ICS therapy

  • Hydrofluoroalkane beclomethasone metred dose inhalerDrug

    Initiation of ICS therapy

  • Chlorofluorocarbon beclomethasone dipropionateDrug

    Initiation of ICS therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total number of exacerbations; exacerbation rate ratio; time to first after IPDTime frame: Two-year outcome period
  2. COPD treatment successTime frame: Two-year outcome period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • General Practice Research Database

    London, London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.